Risperidone Treatment for Military Service Related Chronic Post Traumatic

Status Completed

Clinical Trial Summary

The purpose of this research of 400 participants is to determine whether a drug called risperidone can decrease symptoms of Post-Traumatic Stress Disorder (PTSD). It is a placebo-controlled study, meaning that half of the participants will be assigned to receive a pill that contains no drug. The treatment phase of the study will last for 6 months, during which time participants will continue to receive all their usual treatments in addition to the study treatment and will be asked to complete procedures and assessments (questionnaires, interviews, laboratory tests, physical exams, etc.) related to their PTSD symptoms at various points within the 6-month treatment phase. At the end of the 6-month study, participants will discontinue the study treatment.

Clinical Trial Description

Primary Hypothesis: Risperidone will reduce symptoms of PTSD, relative to placebo, in veterans with military service related chronic PTSD who have been partial or non-responders to antidepressant medications.

Secondary Hypothesis: Risperidone is safe and well-tolerated in veterans with military service related chronic PTSD, and patients will comply with its prescription. As a result, patients will show improvement in the secondary consequences of PTSD for the veteran and for the VA.

Intervention: Usual (PTSD) care plus Risperidone vs usual (PTSD) care plus placebo Study Abstract: Four hundred veterans with the diagnosis of military-related PTSD will be enrolled at 20 VAMC hospitals over a two-year period. An equipoise stratification design will be used to randomize patients in a double-blind manner to risperidone or placebo (~200 patients in each group) for six months of treatment. Usual care will be provided for all patients for treatment of PTSD and other psychiatric and medical disorders. Comparisons between the risperidone and placebo groups will be made at the end of six months to answer the primary question. The sample size is calculated to give 90% power at the two-sided alpha level of 0.05 for the overall test for the CAPS score change.

STUDY UPDATE/NOTES: The study kicked-off in late July 2006 with recruitment expected to begin October 1, 2006.

Oct2006 - Participating sites are seeking approval for the protocol amendment which resulted from the Kick-Off meeting. Patient recruitment at each site will begin as soon as they receive approval of the amendment. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00099983
Study type	Interventional
Source	VA Office of Research and Development
Contact
Status	Completed
Phase	Phase 2
Start date	October 2006
Completion date	January 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01636791` - CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care	Phase 3
Completed	`NCT00870545` - Reintegration: The Role of Spouse Telephone BATTLEMIND Pilot Study	N/A
Completed	`NCT01459705` - Comparing Virtual Reality Exposure Therapy to Prolonged Exposure	N/A
Active, not recruiting	`NCT01216982` - Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders	Phase 2
Completed	`NCT00374738` - Effects of an Alternative Treatment for Military Sexual Trauma on PTSD Symptoms, Neurosteroids and Brain Function	N/A
Not yet recruiting	`NCT00320437` - Intergenerational Transmission of Terror	Phase 1
Completed	`NCT00974402` - Psychotherapy Treatment of Deployment-Related PTSD in Primary Care Settings	N/A
Completed	`NCT01717547` - Strength and Awareness in Action	N/A
Terminated	`NCT01062022` - FOCUS-CI: A Preventive Intervention With Children and Families of the Combat Injured	N/A
Completed	`NCT01565213` - Transdiagnostic Group Treatments for Patients With Common Mental Disorders in Primary Health Care	Phase 3
Recruiting	`NCT01538082` - Role of the Stress in the Development of the Metabolic Syndrome	N/A
Completed	`NCT01667809` - CBT vs RTW Intervention for Patients With Common Subclinical Mental Illness in Primary Care	Phase 3
Completed	`NCT01667822` - Cognitive Behavioral Therapy, Guided Self Help Versus Individual Therapy	Phase 3
Completed	`NCT01277354` - Effectiveness of Cognitive Processing Therapy in Pregnant Women With a History of Pregnancy Loss/Complication	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Risperidone Treatment for Military Service Related Chronic Post Traumatic Stress Disorder — CSP #504

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms